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5Departamento de Cardioloǵıa Hospital de Jerez, Cádiz, Spain
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Objectives. To determine the outcome predictors of in-hospital mortality in acute total occlusion of the left main coronary artery
(ATOLMA) patients referred to emergent angioplasty and to describe the clinical presentation and the long-term outcome of
these patients. Background. ATOLMA is an uncommon angiographic finding that usually leads to a catastrophic presentation.
Limited and inconsistent data have been previously reported regarding true ATOLMA, yet comprehensive knowledge remains
scarce. Methods. )is is a multicenter retrospective cohort that includes patients presenting with myocardial infarction due to a
confirmed ATOLMA who underwent emergency percutaneous coronary intervention (PCI). Results. In the period of the study,
7930 emergent PCI were performed in the five participating centers, and 46 of them had a true ATOLMA (0.58%). At admission,
cardiogenic shock was present in 89% of patients, and cardiopulmonary resuscitation was required in 67.4%. All the patients had
right dominance. Angiographic success was achieved in 80.4% of the procedures, 13 patients (28.2%) died during the cathe-
terization, and the in-hospital mortality rate was 58.6% (27/46). At one-year and at the final follow-up, 18 patients (39%) were
alive, including four cases successfully transplanted. Multivariate analysis showed that postprocedural TIMI flow was the only
independent predictor of in-hospital mortality (OR 0.23, (95% CI 0.1–0.36), p< 0.001). Conclusions. Our study confirms that the
clinical presentation of ATOLMA is catastrophic, presenting a high in-hospital mortality rate; nevertheless, primary angioplasty in
this setting is feasible. Postprocedural TIMI flow resulted as the only independent predictor of in-hospital mortality. In-hospital
survivors presented an encouraging outcome. ATOLMA and left dominance could be incompatible with life.
1. Background
Patients with myocardial infarction (MI) caused by left main
coronary artery (LMCA) represent a high-risk group of
patients, and treatment of such lesions is an issue of debate.
Contemporary randomized controlled trials (RCTs) have
shown that both coronary artery bypass grafting surgery and
percutaneous revascularization (PCI) may be considered
[1, 2]; nevertheless, the availability of PCI offers a reasonable
therapeutic option in patients who are too critically ill to
tolerate surgery [3].
Prior RCTs have never included subjects with the most
critical ofcoronary pathology circumstances: acute total
occlusion of the left main coronary artery (ATOLMA).
ATOLMA is a quite uncommon angiographic finding that
usually leads to a catastrophic presentation. )is entity may
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be susceptible to associated cardiogenic shock (CS), ma-
lignant ventricular arrhythmias, and sudden death unless
there are substantial preexisting intercollaterals and com-
plete reperfusion is rapidly established [3–5].
Only limited and inconsistent data have been reported
regarding to percutaneous treatment of true ATOLMA.
Previously reported studies have been largely confined to
small cohorts and also included subtotal occlusion or critical
stenosis of the LMCA [6–11].
)is study aims to determine the outcome predictors of
in-hospital mortality in true ATOLMA (100% occlusion)
and to describe clinical presentation and long-term prog-
nosis of these patients.
2. Methods
2.1. Study Population and Procedure. )is is a multicenter
retrospective cohort study. )e inclusion criteria included
patients presenting with ST-elevation MI with the culprit
being the unprotected LMCA with a total angiographic
occlusion (100%) who underwent emergency primary PCI.
Patients with an LMCA subtotal occlusion, previous
patent coronary artery bypass grafting, or iatrogenic acute
ATOLMA were excluded.
An independent investigator blinded to all data, except
for the coronary angiograms, reviewed all angiograms. )e
study was carried out in accordance with the principles of
the Declaration of Helsinki. )e study protocol was ap-
proved by the ethics committee.
Angiographic success was defined as a residual stenosis
of <30% with a thrombolysis in myocardial infarction
(TIMI) flow ≥2.
Two experienced interventional cardiologists retro-
spectively evaluated the angiographies in a blinded manner
to classify collateral circulation (CC) into grades. Dis-
agreement between these assessments was resolved by a
third interventional cardiologist. )e CC was graded
according to Rentrop’s classification: grade 0, no filling of the
occluded vessel; grade 1, filling of the side branches; grade 2,
partial filling of the epicardial vessel; grade 3, complete filling
of the epicardial vessel by collateral [12].
To complete follow-up and to determine the clinical
events and vital status of the patients, electronic medical
records, scheduled visits, and telephone interviews were used.
)e primary aim of the study was to determine the
significant predictors of in-hospital total mortality. )e
secondary aims were to describe the incidence and clinical
presentation of these patients and to evaluate long-term
mortality and major adverse events (MACE) encompassing
all-cause mortality, cardiac transplant, new-onset MI, target
lesion revascularization (TLR), and definite or probable
stent thrombosis (ST) according to the ARC criteria [13].
2.2. Statistical Methods. Data were expressed as mean-
± standard deviation for continuous variables and compared
using the unpaired t-test. Categorical variables were
expressed as numbers or percentages and compared using
chi-square analysis or Fisher’s exact test.
A multiple logistic regression analysis was performed to
identify independent variables associated with in-hospital
mortality.
Variables related to the dependent variable in univariate
analysis (p< 0.05) were included in the multivariate models.
Survival curves were generated by the Kaplan–Meier
method, and differences between groups were analyzed with
the log-rank test; a landmark analysis was performed with a
landmark of 30 days among patients who were survivors or
MACE-free at this time. A p value< 0.05 was considered
statistically significant. All statistical analyses were per-
formed using SPSS version 22.0 (SPSS Inc., Chicago, IL).
3. Results
3.1. Incidence and Presentation. Since Jan 2005, in two of the
five participating centers, and since Jan 2011, in the other three
centers, to Dec 2019, primary angioplasty was performed in
7930 patients; 131 (1.6%) of those were caused by acute un-
protected LMCA disease and 46 of those patients had a true
ATOLMA and were included in the present study (0.58%).
Clinical characteristics of the overall study population are
shown in Table 1. )e prevalence of the main cardiovascular
risk factors and the presence of a prior history of ischemic
cardiopathy were found to be relatively low. )e predominant
symptom at presentation was chest pain in 47.8%. Forty-one
patients (89%) developed CS, only one patient presented in
Killip class II (2.1%), and the rest of the patients (4/46) had a
Killip score 3. Electrocardiograms at presentation were avail-
able for only 18 patients. Anterolateral STelevation was present
in 15 patients (83%), ST-segment elevation in lead aVR in 10
patients (55%), left bundle branch block (LBBB) in three cases
(17%), and lateral ST-segment depressions showing signs of
extensive transmural ischemia in one patient (5.5%).
Mechanical support devices were performed in patients
with a very poor haemodynamic condition; all of them pre-
sented Killip class IV (21/21, 100%), and the mean systolic
pressure was 61± 10mmHg. Intra-aortic balloon pump and
extracorporeal membrane oxygenation (ECMO) were used in
19 (41.3%) and 3 (6.5%) cases, respectively. ECMO was suc-
cessfully used as a bridge for transplantation in two patients.
37% (17/23) of the patients in which CC was assessed
before performing PCI had a Rentrop score of 0, 13% (3/23)
had a Rentrop 1, one patient had a Rentrop 2, and the patient
who presented a Killip score of two had a Rentrop 3.
3.2. Procedural Data. Treatment and procedural charac-
teristics are shown in Table 2. Most of the procedures were
performed by the femoral approach (29/46, 63%) and using a
6-French guiding catheter (37/46, 80.5%). Intracoronary
imaging was performed in order to optimize the final result
in five cases (11%): intravascular ultrasound in four cases
and optical coherence tomography in one (Table 2).
PCI with stent implantation was performed in 69.6%
(32/46) of the procedures. Most of the cases received a drug-
eluting stent (DES) (25/32, 78%). Exceptionally, in a patient
with Rentrop 3, a bioresorbable stent was successfully
implanted (Figure 1). Twenty-two patients presented a
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multivessel disease, andmultivessel PCI was performed in 12
of them (12/22, 58.3%).
3.3. Mortality and Major Cardiovascular Events. )irteen
patients (28.2%) died in the catheterization laboratory
during the procedure, and 7 (15.2%) died in the following 24
hours due to pump failure. Seven patients (15.2%) died
during hospitalization, between the second and the twenty-
sixth day due to CS (5/7, 71%) and nosocomial sepsis (2/7,
28.5%). )e in-hospital mortality rate was 58.6% (27/46).
Two patients with INTERMACS profile 3 dependent on
ECMO had an emergency transplant due to refractory CS on
the 14th and on the 30th day, respectively.
Table 1: Clinical and angiographic characteristics.
Overall (n� 46)
In-hospital mortality
Yes (n� 27) No (n� 19) p
Age, y (SD) 62.8± 12 65± 5 59± 4.8 0.1
Male, n (%) 36 (78) 20 (74) 16 (84) 0.5
Diabetes, n (%) 7 (15.2) 6 (22) 1 (5) 0.2
Hypertension, n (%) 16 (34.8) 7 (37) 9(33) 0.8
Dyslipidemia, n (%) 12 (26.1) 9 (33) 3 (16) 0.2
Smoking, n (%) 23 (50) 12 (44) 11 (58) 0.3
Prior IC (%) 3 (6.5) 3 (11) 0 (0) 0.25
Presentation (%)
Cardiogenic shock 41 (89) 26 (96) 15 (79) 0.08
Heart rate (bpm)∗ 106.5± 15 109± 14 102± 15 0.2
Systolic blood pressure (mmHg)∗ 70.5± 20 67± 17 75.5± 24 0.3
Cardiac arrest at presentation 8 (17.4) 4 (15) 4 (21) 0.5
Ventricular tachyarrhythmia 17 (37) 10 (37) 7 (37) 1
TIMI flow 0 at presentation 100% 27 (100) 19 (100) 1
Multivessel disease 21 (45.7) 11 (41) 11 (58) 0.37
Right coronary disease 9 (19.6) 4 (15) 5 (26) 0.45
Right coronary dominance 46 (100%) 27 (100) 19 (100) 1
Rentrop 0 17/23 (74) 15 (79) 2 (50) 0.2
Symptom to balloon 187± 51 208.5± 81 158± 49 0.3
FMC to balloon 117± 52 139.7± 90 87.7± 19 0.3
∗Data available from 23 patients. IC: ischemic cardiopathy; OTI: orotracheal intubation; CC: collateral circulation; FMC: first medical contact.
Table 2: Treatment and procedural characteristics.
Overall (n� 46)
In-hospital mortality
Yes (n� 27) No (n� 19) p
Orotracheal intubation 31 (67.4) 23 (85) 7 (37) 0.06
Ventricular assistance device 21 (45.6) 11 (40) 10 (53) 0.4
IABP 20 (43.5) 11 (41) 9 (47.4) 0.65
ECMO 3 (6.5) 0 (0) 3 (15.8) 0.06
CPR 31 (67.4) 21 (78) 10 (53) 0.07
GP IIa/IIIb inhibitors 22 (47.8) 12 (44) 15 (56) 0.2
Vasoactive drugs 41 (89.2) 25 (96) 15 (79) 0.07
Angioplasty
Angiographic success 37 (80.4) 18 (67) 19 (100) <0.001
Radial approach 16 (34.8) 6 (22) 10 (53) 0.03
Seven French catheter 8 (17.4) 2 (7) 6 (32) 0.05
LM stent deployed 32 (69.6) 15 (56) 17 (90) 0.01
LM bare metal stent 7 (21.8) 2 (13) 5 (30) 0.4
LM stent diameter (mm) 3.5± 0.4 3.5± 0.5 3.5± 0.2 1
Complex LM technique 6 (13) 3 (11) 3 (16) 0.7
LM stent predilation 15/32 (47) 10 (67) 13 (77) 0.7
LM stent postdilation 15/32(47) 7 (47) 8 (47) 1
)rombus aspiration 19 (41.7) 13 (48) 6 (32) 0.2
Intracoronary imaging 5 (10.9) 1 (4) 4 (21) 0.14
Contrast volume (ml) 177± 132 189± 161 161± 87 0.6
Final TIMI flow 2.2± 0.3 1.78± 0.4 2.8± 0.2 <0.001
Final TIMI flow 3 23 (50) 8 (30) 19 (70) 0.001
IABP: intra-aortic balloon pump; ECMO: extracorporeal membrane oxygenation; CPR: cardiopulmonary resuscitation; LM: left main.
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Mean follow-up, among the survivors, was 31 months
(interquartile range, 1.4–67 month). One patient, in which a
BMS was successfully implanted, died suddenly on day 19
after discharge. )erefore, 16 patients (34.7%) survived
without transplantation at 30-day follow-up.
Among the survivors, three patients were admitted to
the hospital due to heart failure (HF) on the 21st day and on
the second month after discharge. Two patients, with re-
fractory HF, were transplanted in the second and the sixth
month. Another patient with a BMS restenosis was suc-
cessfully treated with a new DES, seven months after
discharge. No other patient died during the first-year
follow-up.
)erefore, at one-year follow-up, 18 patients (39%) were
still alive, including the four cases successfully transplanted,
and only 11 patients (24%) were alive and free of MACE or
admission for HF. At final follow-up, 10 (21.7%) patients
were alive and free of any event (Table 3).)e patient treated
with a bioresorbable stent was asymptomatic and free of
event at 40-month follow-up.
Univariate predictors of in-hospital mortality are re-
flected in Tables 1 and 2. Multivariate analysis showed that
postprocedural TIMI flow was the only independent pre-
dictor of in-hospital mortality (Table 4).
CC was not a significant univariate predictor of mor-
tality; nonetheless, CS (100% vs. 50%, p � 0.01) and one-year
MACE were significantly higher in patients with Rentrop 0
at the initial angiography (81% vs. 19%, p � 0.01).
Kaplan–Meier MACE-free and survival curves at 30-day
follow-up showed that both events were significantly lower
in patients with a postprocedural TIMI flow 3 compared to
those with a final TIMI flow ≤3 (Figure 2).
(a) (b) (c)
(d) (e) (f )
Figure 1: (a) )e angiography showed an acute thrombotic occlusion of the unprotected left main coronary artery (ATOLMA). (b) A
dominant right coronary artery that contributed Rentrop 3 collateral circulation. (c) )e OCT revealed a correct apposition of the
bioresorbable vascular scaffold (Absorb 3.5× 28mm). (d) Final angiographic result. (e) At 40-month follow-up, an excellent result is
maintained in the angiography. (f ) )e OCT showed reabsorption in process with partial disappearance of the black boxes.
Table 3: Outcomes of the study population.
In-hospital outcomes, n (%)
In-cath lab mortality, N (%) 13 (28.2)
In-hospital total mortality 27 (58.6)
Cardiac arrest 31 (67.4)
Cardiac transplant 2 (4.3)
Major bleeding complications 0 (0)
One-year outcomes, n (%)
Total mortality 28 (60.9)
Cardiac transplant 4 (8.7)
TLR 1 (2.2)
Definite or probable ST 1 (2.2)
Non-fatal MI 1 (2.2)
MACE 33 (71.7)
Heart failure admission 4 (8.7)
Non-fatal stroke 0 (0)
Total follow-up outcome, n (%)
Total mortality 28 (60.9)
MACE 34 (73.9)
Heart failure admission 5 (10.8)
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Data for dual antiplatelet therapy (DAPT) were missing
in 11 patients; 51% (18/35) of the patients were treated with
ticagrelor, 40% with clopidogrel (14/27), and the rest with
prasugrel (3/35, 9%)
4. Discussion
Emergency presentation with occlusion of the LMCA is a
dramatic and catastrophic coronary event. Except the de-
scriptive cohort reported by Edes et al. [14], the rest of the
existing literature includes patients with severe stenosis or
subtotal occlusion of the LMCA. As far as we concern, this is
the largest reported cohort including exclusively patients with a
true ATOLMA (TIMI flow 0) referred to primary angioplasty.
4.1. Incidence. Previous studies have reported that the in-
cidence of ST-elevation myocardial infarction (STEMI)
caused by LMCA ranged from 0.8 to 2.5% in patients un-
dergoing cardiac catheterization [3, 6, 11, 15–17].
In the present study, a lower incidence was found
(0.58%). )e discrepancy is related to the fact that previous
studies also included subtotal occlusion or critical stenosis of
the LMCA, while in this cohort, exclusively, patients with a
true ATOLMA referred to primary angioplasty were
recruited [4, 6–8, 10, 11, 16].
However, the true incidence of ATOLMA may be
underestimated because most of the patients in this clinical
setting died before angiography can be performed.
4.2. Clinical Presentation. ATOLMA usually results in se-
vere ventricular dysfunction leading to a rapid haemody-
namic deterioration and a catastrophic clinical presentation
[4, 6].
Previously reported studies showed an incidence of CS
ranged between 62 and 83% [5–7, 11, 16–19] and of me-
chanical ventilatory support requirement (invasive or
noninvasive) between 23 and 89% [6, 11, 16].
Our study, in agreement with that reported by Edes et al.,
including strictly true ATOLMA, reflects even a poorer
clinical presentation: 89% (41/46) of the patients developed
CS [14]; 67.4% (31/46) required orotracheal intubation and
invasive ventilatory support, and cardiopulmonary resus-
citation maneuvers were necessary in 67.4% (31/46) patients.
All except one patient presented Killip class III-IV,
which reflect the poor clinical status of these patients at
presentation. ATOLMA should be suspected in patients with
STEMI accompanied by these potentially devastating pre-
sentations, and an early invasive strategy should be en-
couraged in these patients [3, 6, 8].
4.3. Prognosis. )e “LMCA shock syndrome” originally
described by Quigley et al. in 1993 showed that when STEMI
occurs with CS and severe LMCA stenosis, prognosis, re-
gardless of management, was extraordinarily poor with a
mortality rate of 94% [5, 11, 20, 21].
A more contemporary approach using new-generation
stents, haemodynamic support, and new treatments, in
Table 4: Predictors of in-hospital mortality (multivariate analysis).
In-hospital mortality
HR (95% CI) p
Final TIMI flow 0.23 (0.1–0.36) <0.01
LM stent 0.1 (−0.21 to 4.3) 0.5
Radial approach 0.25 (0.005–0.5) 0.054
Angiographic success 0.12 (−0.5 to 0.8) 0.6
Log-rank test p < 0.001 Log-rank test p < 0.001
No. at risk
TIMI 3 23 18 16 15
TIMI < 3 23 5 3 2
No. at risk
TIMI 3 23 18 17 16
TIMI < 3 23 5 3 3
Final TIMI flow < 3 
Final TIMI flow 3 
Final TIMI flow < 3 






























Figure 2: Kaplan–Meier curves showing that the final TIMI flow 3 was significantly associated with 30-day death and 30-day MACE (log-
rank test p≤ 0.01 for both).
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particular new antiplatelet therapies, and also the increased
experience with treating LMCA percutaneously and PCI in
the context of STEMI, have slightly improved results and
prognosis. However, STEMI caused by LMCA disease still
has a poor prognosis, with the exception of the study by Liu
et al., in which a surprisingly low in-hospital mortality rate
(5.1%) and 30-day mortality (6.2%) were found [8]. Most of
the studies reported an in-hospital mortality rate of 31–58%
and a 30-day mortality of 36–63%
[3, 6, 7, 10, 11, 16–18, 22–25].
Little evidence exists regarding the mortality rate in true
ATOLMA (TIMI 0). However, as expected, the limited
available information shows a poorer prognosis in this
scenario when compared with critical or subtotal LMCA
occlusion. De Luca et al. reported a mortality rate of 60% in
the subgroup of patients with a TIMI flow 0, very similar to
that reported by Edes et al. (56%) and Yip et al. (62%, 5/8) in
those subgroup of patients.
Two more contemporary studies revealed a similar
outcome: YAP et al. found a mortality rate of 54% (22/41)
and Homorodean et al. 63% (12/19), despite these results
referring to TIMI 0-1 patients and not exclusively to TIMI 0
cases [6, 10, 11, 14, 18].
Concordantly with previous observations, in the present
study, although restoration of the coronary flow is mostly
successful (80.4%), a rather significant in-hospital mortality
was observed (58.6%, 27/46). But, even the true mortality of
ATOLMA may be underestimated as many patients could
not be taken to the catheterization laboratory before dying.
In this cohort, patients surviving the initial hospitali-
zation showed an encouraging prognosis; only one patient
died during follow-up (6%, 1/19), which is comparable to the
findings previously reported with a survival rate of 83–90%
among in-hospital survivors [3, 5, 6, 11, 14, 17, 22, 25].
4.4. Predictors of Mortality
4.4.1. Collateral Circulation. )e role of early recruited CC
in STEMI remains controversial. Some previous reports
have shown lower mortality and morbidity rates in well-
collateralized patients, but others have not [26–29].
Regarding LMCA PCI in the setting of primary angio-
plasty, it has been suggested that the presence of well-de-
veloped collateralization is a crucial predictor of survival
[4, 5, 11, 16, 18, 30].
As only true ATOLMA was included in our study, the
clinical presentation was often devastating, and the operator
decided not to perform a contralateral injection before the
LMCA PCI in 23/46. )erefore, CC grade information was
missing in 50% of the procedures, and well-developed CC
(Rentrop class ≥2) was confirmed only in two cases (8.7%).
Nevertheless, the absence of CC (Rentrop 0) was signifi-
cantly higher in patients with CS at presentation and was
related to one-year MACE, which highlights the role that CC
may play in ATOLMA patients. Nonetheless, in our study,
since the CC grade was assessed only in 50% of the pro-
cedures, CC was not a univariate predictor of in-hospital
mortality and consequently excluded in the multivariate
model. Certainly, the role of CC in ATOLMA remains to be
further elucidated.
4.4.2. Right Dominance. In STEMI treated with primary
angioplasty, right coronary dominance confers a better
prognosis than left dominance, and it is explained by the fact
that right dominance has a greater division of vasculature
supplying the left ventricle (into 3 “parts”), whereas left
dominance means that most of the myocardium is essen-
tially dependent on 2 arteries [31].
Concerning ATOLMA, this vasculature division de-
pendent on coronary dominance becomes even more rel-
evant since LMCA supplies those two arteries.)erefore, it is
not surprising that dominance has been related to survival in
patients with subtotal LMCA occlusion [11]. In true
ATOLMA, it has been suggested that only patients with right
dominance will survive to receive a diagnosis and invasive
treatment [5, 14].
In agreement with these observations, we found that
100% (46/46) of the patients included in our study had right
dominance, probably because left main dominance patients
may die before being transferred to cardiac catheterization.
Our findings and previous results suggest that most probably
ATOLMA and left dominance could be incompatible with
life, especially in the absence of well-developed CC [14].
4.4.3. Final TIMI Flow. TIMI flow grades have been shown
to have significant prognostic implications among patients
undergoing reperfusion therapy for STEMI [32–34], and
similar results have been reported in the setting of primary
angioplasty in LMCA [6, 10, 16].
Concordantly, our study proved that postprocedural
TIMI flow in ATOLMA patients was the only independent
predictor of in-hospital mortality in the multivariate model.
)e TIMI flow achieved was also significantly related to
short-term MACE and mortality as reflected in the
Kaplan–Meier curve (Figure 2). )erefore, restoration of
TIMI 3 flow is crucial in this situation. However, TIMI flow 3
was only achieved in 50% (23/46) of our patients, which is
significantly lower than general STEMI where TIMI 3 is
obtained in >90% of procedures, or with not-true ATOLMA
where it ranges from 66% to 86% [6, 10, 11, 18, 34].
Obtaining a final TIMI 3 flow can be challenging in this
catastrophic scenario, but according to our data and pre-
vious knowledge reported, every effort must be made to
achieve this goal.
5. Limitations
)is was a retrospective study with a small sample size. Like
all observational studies, the present study is prone to biases
from its nonrandom assignment of exposures. CC was not
assessed before PCI in 50% of the procedures. Furthermore,
while this study focused on in-hospital mortality, the un-
questionably high prehospital mortality was not quantified.
One inherent limitation is that there are differences in the
nature and the type of hospital facilities (e.g., intra-aortic
balloon pump, ECMO, or in-site transplant availability).)e
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long period of inclusion may have introduced bias due to
changes in technology and management.
6. Conclusions
Clinical presentation of ATOLMA patients with MI referred
to primary angioplasty is usually catastrophic; most patients
presented in CS and CPR maneuvers and OTI were fre-
quently required.
Emergency primary PCI provides a feasible treatment
option in this context, yet in-hospital mortality remains
quite high. Since the final TIMI flow was the only inde-
pendent predictor of in-hospital mortality, every effort must
be made to achieve this goal. Long-term mortality rates for
survivors are reasonably encouraging.
Interestingly, all of our patients had right coronary
dominance, suggesting that presumably ATOLMA and left
dominance could be incompatible with life.
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0057-017), Por la Consejeŕıa de Salud y por el Fondo
Europeo de Desarrollo Regional (FEDER).
Supplementary Materials
Two representative example cases of left main acute oc-
clusion have been submitted as the supplementary material.
One of them with the TIMI 3 flow result and the other with a
TIMI 1 flow result. Both cases were summarized in a one-
minute video with titles and subtitles explaining the pro-
cedures. (Supplementary Materials)
References
[1] G. W. Stone, A. P. Kappetein, and J. F. Sabik, “Five-year
outcomes after PCI or CABG for left main coronary disease,”
8e New England Journal of Medicine, vol. 381, no. 19,
pp. 1820–1830, 2019.
[2] N. R. SerruysPocock, T. Mäkikallio, and M. M. Lindsay,
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vencionismo percutáneo urgente sobre el tronco coronario
izquierdo no protegido. Factores predictores de mortalidad y
análisis del shock cardiogénico,” Revista Española de
Cardiologı́a, vol. 62, no. 10, pp. 1118–1124, 2009.
[8] H.-W. Ruiz, Y.-L. Han, Q.-M. Jin et al., “One-year outcomes
in patients with ST-segment elevation myocardial infarction
caused by unprotected left main coronary artery occlusion
treated by primary percutaneous coronary intervention,”
Chinese Medical Journal, vol. 131, no. 12, pp. 1412–1419, 2018.
[9] N.Wang, A. Badiye, D. R. Yavagal, and C. E.Mendoza, “Stent-
based mechanical thrombectomy in left main coronary artery
thrombus presenting as ST-segment elevation myocardial
infarction,” JACC: Cardiovascular Interventions, vol. 10, no. 3,
pp. 302-303, 2017.
[10] J. Yap, G. D. Singh, J.-S. Kim et al., “Outcomes of primary
percutaneous coronary intervention in acute myocardial in-
farction due to unprotected left main thrombosis: the Asia-
Pacific Left Main ST-Elevation Registry (ASTER),” Journal of
Interventional Cardiology, vol. 31, no. 2, pp. 129–135, 2018.
[11] H.-K. Soni, C.-J. Wu, M.-C. Chen et al., “Effect of primary
angioplasty on total or subtotal left main occlusion,” Chest,
vol. 120, no. 4, pp. 1212–1217, 2001.
[12] K. P. Chang, F. Feit, W. Sherman, and J. C. )ornton, “Serial
angiographic assessment of coronary artery obstruction and
collateral flow in acute myocardial infarction. Report from the
second Mount Sinai-New York University reperfusion trial,”
Circulation, vol. 80, no. 5, pp. 1166–1175, 1989.
[13] D. E. Cutlip, S. Windecker, R. Mehran et al., “Clinical end
points in coronary stent trials,” Circulation, vol. 115, no. 17,
pp. 2344–2351, 2007.
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M. A. Restrepo-Córdoba et al., “Impacto de la circulación
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